Abstract |
Two consecutive, open, prospective trials of intermittent azithromycin (600 mg), usually given Monday, Wednesday, and Friday (TIW) for Mycobacterium avium complex (MAC) lung disease were initiated in human immunodeficiency virus-negative patients. Regimen A consisted of TIW azithromycin and daily ethambutol (15 mg/kg/day), daily rifabutin (300 mg/day), and initial twice weekly (BIW) streptomycin. Regimen B consisted of TIW azithromycin, TIW ethambutol (25 mg/kg/dose), TIW rifabutin (600 mg/dose), and initial BIW streptomycin. Of 19 patients enrolled in regimen A who completed at least 6 months of therapy, 14 (74%) had sputum samples become culture-negative. Of 39 patients enrolled in regimen B who completed at least 6 months of therapy, 24 (62%) had sputum conversion. These sputum conversion rates are comparable to previous rates at 6 months in patients receiving daily clarithromycin- or azithromycin-containing regimens. No resistance to azithromycin emerged with either regimen. This is the first study to demonstrate the efficacy of intermittent administration of medication for MAC lung disease.
|
Authors | D E Griffith, B A Brown, D T Murphy, W M Girard, L Couch, R J Wallace Jr |
Journal | The Journal of infectious diseases
(J Infect Dis)
Vol. 178
Issue 1
Pg. 121-6
(Jul 1998)
ISSN: 0022-1899 [Print] United States |
PMID | 9652431
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Rifabutin
- Azithromycin
- Ethambutol
- Streptomycin
|
Topics |
- Anti-Bacterial Agents
(administration & dosage, therapeutic use)
- Azithromycin
(administration & dosage, therapeutic use)
- Drug Administration Schedule
- Drug Therapy, Combination
- Ethambutol
(administration & dosage, therapeutic use)
- Female
- Humans
- Lung Diseases
(drug therapy)
- Male
- Middle Aged
- Mycobacterium avium-intracellulare Infection
(drug therapy)
- Prospective Studies
- Rifabutin
(administration & dosage, therapeutic use)
- Streptomycin
(administration & dosage, therapeutic use)
- Treatment Outcome
|